person · Reporting owner
Harrington Lisa Hatton
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CN Healthy Food Tech Group Corp.IROH · Entity 5989 | Director | December 27, 2023 | December 29, 2023 |
| Niagen Bioscience, Inc.CDXC · Entity 6146 | GENERAL COUNSEL | March 15, 2021 | March 17, 2021 |
| Slam Corp.SLAM · Entity 54573 | Director | April 25, 2023 | April 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CN Healthy Food Tech Group Corp.
Report date December 27, 2023 · Filed December 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThrough Bengochea SPAC Sponsors I LLC, the sponsor ("Sponsor") of the registrant (the "Company") | 20,000 |
Reported balance
Holding disclosure · report date 2023-12-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,000 |
Niagen Bioscience, Inc.
Report date March 15, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.83 · Expires 2031-03-14 | Direct | 15,000 |
Reported balance
After 2021-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-15 · Grant · Acquired 15,000 · Balance 15,000 F1: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month.
Slam Corp.
Report date April 25, 2023 · Filed April 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-04-25 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252727) under the heading "Description of Securities-Founder Shares", the Class B ordinary shares, par value $0.0001 (the "Class B Shares"), will automatically convert into Class A ordinary shares, par value $0.0001, of the issuer at the time of the issuer's initial business combination transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2: On April 25, 2023, the Sponsor sold 10,000 Class B Shares to Lisa Hatton Harrington for $10,000, or approximately $1.00 per share, in connection with Ms. Harrington's appointment to the board of directors of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-252727) under the heading "Description of Securities-Founder Shares", the Class B ordinary shares, par value $0.0001 (the "Class B Shares"), will automatically convert into Class A ordinary shares, par value $0.0001, of the issuer at the time of the issuer's initial business combination transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
F2: On April 25, 2023, the Sponsor sold 10,000 Class B Shares to Lisa Hatton Harrington for $10,000, or approximately $1.00 per share, in connection with Ms. Harrington's appointment to the board of directors of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2021 Filed Mar 17, 2021 18:49 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001415889-21-001554 · form4-03172021_030321.xml · derivative · entry 1 Harrington Lisa Hatton · CIK 0001850211 · GENERAL COUNSEL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-14 F1 · derivative.exercise_date: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.